US98943L1070
© Globe Newswire
03.02.2026
ZNTL
LISTED
NASDAQ
Zentalis Pharmaceuticals to Participate in Upcoming Investor Conference
News Preview
SAN DIEGO, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical oncology innovator advancing late-stage development of investigational first-in-class WEE1 inhibitor azenosertib as a biomarker-driven treatment approach for ovarian cancer, today announced that members of the management team will participate i...
Themefolio
Profiler
Peergroup
© Globe Newswire
10.11.2025
ZNTL
LISTED
NASDAQ
Zentalis Pharmaceuticals Reports Third Quarter 2025 Financial Results and Operational Progress
News Preview
DENALI Phase 2 trial evaluating azenosertib in patients with Cyclin E1-positive PROC remains on track with topline data anticipated by year end 2026, with the potential to support an accelerated approval, subject to FDA feedback...
Themefolio
Profiler
Peergroup
© Globe Newswire
03.11.2025
ZNTL
LISTED
NASDAQ
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
News Preview
SAN DIEGO, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company developing a potentially first-in-class WEE1 inhibitor for patients with ovarian cancer and other tumor types, today announced that on November 3, 2025, the Compensation Committee of Zentalis’ Board of Directors...
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
Knowing what matters
Short sale statistics, hedge fund activities and much more user-friendly information
© Globe Newswire
13.10.2025
ZNTL
LISTED
NASDAQ
Zentalis Pharmaceuticals Announces Four Azenosertib Posters Presentations at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
News Preview
Presentations feature data from first-in-human Phase 1 study including Cyclin E1 biomarker findings, supporting late-stage development of azenosertib Presentations feature data from first-in-human Phase 1 study including Cyclin E1 biomarker findings, supporting late-stage development of azenosertib...
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
23.01.2026
© Globe Newswire
01.10.2025
ZNTL
LISTED
NASDAQ
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
News Preview
SAN DIEGO, Oct. 01, 2025 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company developing a potentially first-in-class and best-in-class WEE1 inhibitor for patients with ovarian cancer and other tumor types, today announced that on October 1, 2025, the Compensation Committee of Zentalis’ Bo...
Themefolio
Profiler
Peergroup
© Globe Newswire
02.09.2025
ZNTL
LISTED
NASDAQ
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
News Preview
SAN DIEGO, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company developing a potentially first-in-class and best-in-class WEE1 inhibitor for patients with ovarian cancer and other tumor types, today announced that on September 2, 2025, the Compensation Committee of Zentalis’...
Themefolio
Profiler
Peergroup
© Globe Newswire
28.08.2025
ZNTL
LISTED
NASDAQ
Zentalis Pharmaceuticals to Participate in Upcoming Investor Conferences
News Preview
SAN DIEGO, Aug. 28, 2025 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company developing a potentially first-in-class and best-in-class WEE1 inhibitor for patients with ovarian cancer and other tumor types, today announced that members of the management team will participate in the followi...
Themefolio
Profiler
Peergroup
© Globe Newswire
26.08.2025
ZNTL
LISTED
NASDAQ
Zentalis Pharmaceuticals Appoints James B. Bucher, JD, as Chief Legal Officer and Corporate Secretary
News Preview
Seasoned life sciences legal executive brings extensive public company experience, including broad strategic and financial transaction expertise Seasoned life sciences legal executive brings extensive public company experience, including broad strategic and financial transaction expertise...
Themefolio
Profiler
Peergroup
© Globe Newswire
01.07.2025
ZNTL
LISTED
NASDAQ
Zentalis Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
News Preview
SAN DIEGO, July 01, 2025 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company developing a potentially first-in-class and best-in-class WEE1 inhibitor for patients with ovarian cancer and other tumor types, today announced that on July 1, 2025, the Compensation Committee of Zentalis’ Board...
Themefolio
Profiler
Peergroup
© Globe Newswire
02.06.2025
ZNTL
LISTED
NASDAQ
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
News Preview
SAN DIEGO, June 02, 2025 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company developing a potentially first-in-class and best-in-class WEE1 inhibitor for patients with ovarian cancer and other tumor types, today announced that on June 2, 2025, the Compensation Committee of Zentalis’ Board...
Themefolio
Profiler
Peergroup
© Globe Newswire
01.04.2025
ZNTL
LISTED
NASDAQ
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
News Preview
SAN DIEGO, April 01, 2025 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company developing a potentially first-in-class and best-in-class WEE1 inhibitor for patients with ovarian cancer and other tumor types, today announced that on April 1, 2025, the Compensation Committee of Zentalis’ Boa...
Themefolio
Profiler
Peergroup
© Globe Newswire
26.03.2025
ZNTL
LISTED
NASDAQ
Zentalis Pharmaceuticals Reports Full Year 2024 Financial Results and Operational Updates
News Preview
Positive azenosertib clinical data demonstrated clinically meaningful results in patients with Cyclin E1+ platinum-resistant ovarian cancer (PROC)...
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© Globe Newswire
25.03.2025
ZNTL
LISTED
NASDAQ
Zentalis Pharmaceuticals to Present Multiple Posters at the American Association for Cancer Research (AACR) Annual Meeting 2025
News Preview
One poster demonstrating cell-free DNA molecular response as a potential surrogate endpoint to measure clinical efficacy of azenosertib in patients with high-grade serous ovarian cancer (HGSOC)...
Themefolio
Profiler
Peergroup
© Globe Newswire
15.03.2025
ZNTL
LISTED
NASDAQ
Zentalis Pharmaceuticals Presents Updated Clinical Data at the Society of Gynecologic Oncology 2025 Annual Meeting on Women’s Cancer
News Preview
Azenosertib median duration of response (mDOR) updated to 6.3 months in the ongoing DENALI Part 1b clinical trial in patients with platinum-resistant ovarian cancer (PROC) and continues to demonstrate an objective response rate (ORR) of ~35% in response-evaluable patients...
Themefolio
Profiler
Peergroup
© Globe Newswire
03.03.2025
ZNTL
LISTED
NASDAQ
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
News Preview
SAN DIEGO, March 03, 2025 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company developing a potentially first-in-class and best-in-class WEE1 inhibitor for patients with ovarian cancer and other tumor types, today announced that on March 3, 2025, the Compensation Committee of Zentalis’ Boa...
Themefolio
Profiler
Peergroup
© Globe Newswire
03.02.2025
ZNTL
LISTED
NASDAQ
Zentalis Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
News Preview
SAN DIEGO, Feb. 03, 2025 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company discovering and developing clinically differentiated small molecule therapeutics targeting fundamental biological pathways of cancers, today announced that on February 3, 2025, the Compensation Committee of Zenta...
Themefolio
Profiler
Peergroup
© Globe Newswire
29.01.2025
ZNTL
LISTED
NASDAQ
Zentalis Pharmaceuticals Shares Updated Clinical Data Demonstrating Meaningful Azenosertib Activity in Cyclin E1+, Platinum-Resistant Ovarian Cancer
News Preview
Results from DENALI Part 1b show an Objective Response Rate (ORR) of ~35% in response-evaluable, heavily-pretreated patients with Cyclin E1+ platinum-resistant ovarian cancer (PROC)...
Themefolio
Profiler
Peergroup
© Globe Newswire
28.01.2025
ZNTL
LISTED
NASDAQ
Zentalis Pharmaceuticals Announces Strategic Restructuring to Support Late-Stage Azenosertib Development
News Preview
Extended cash runway into late 2027, beyond a potentially registration-enabling azenosertib data readout from DENALI Part 2...
Themefolio
Profiler
Peergroup
© Globe Newswire
09.01.2025
ZNTL
LISTED
NASDAQ
Zentalis Pharmaceuticals Announces Azenosertib Fast Track Designation and Virtual Corporate Event to Present Updated Data from Azenosertib Clinical Studies
News Preview
Azenosertib Fast Track Designation granted for Cyclin E1 positive patients by U.S. Food and Drug Administration (FDA)...
Themefolio
Profiler
Peergroup
© Globe Newswire
02.01.2025
ZNTL
LISTED
NASDAQ
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
News Preview
SAN DIEGO, Jan. 02, 2025 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company discovering and developing clinically differentiated small molecule therapeutics targeting fundamental biological pathways of cancers, today announced that on January 2, 2025, the Compensation Committee of Zental...
Themefolio
Profiler
Peergroup
© Globe Newswire
12.12.2024
ZNTL
LISTED
NASDAQ
Zentalis Pharmaceuticals Announces Key Management Appointments
News Preview
Wendy Chang appointed Chief People Officer; Haibo Wang appointed Chief Business Officer Wendy Chang appointed Chief People Officer; Haibo Wang appointed Chief Business Officer...
Themefolio
Profiler
Peergroup
© Globe Newswire
02.12.2024
ZNTL
LISTED
NASDAQ
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
News Preview
SAN DIEGO, Dec. 02, 2024 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company discovering and developing clinically differentiated small molecule therapeutics targeting fundamental biological pathways of cancers, today announced that on December 2, 2024, the Compensation Committee of Zenta...
Themefolio
Profiler
Peergroup
© Globe Newswire
01.11.2024
ZNTL
LISTED
NASDAQ
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
News Preview
SAN DIEGO, Nov. 01, 2024 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company discovering and developing clinically differentiated small molecule therapeutics targeting fundamental biological pathways of cancers, today announced that on November 1, 2024, the Compensation Committee of Zenta...
Themefolio
Profiler
Peergroup
© Globe Newswire
16.09.2024
ZNTL
LISTED
NASDAQ
Zentalis Pharmaceuticals Announces FDA Has Lifted Partial Clinical Hold on Azenosertib Studies
News Preview
Company on track to present data from key clinical studies of azenosertib in the fourth quarter of 2024 Company on track to present data from key clinical studies of azenosertib in the fourth quarter of 2024...
Themefolio
Profiler
Peergroup
© Globe Newswire
09.09.2024
ZNTL
LISTED
NASDAQ
Zentalis Pharmaceuticals to Present Preclinical Azenosertib Data at ESMO 2024
News Preview
Azenosertib shows synergistic anti-tumor effects in combination with topoisomerase I (TOP1) inhibitor-based antibody drug conjugates Azenosertib shows synergistic anti-tumor effects in combination with topoisomerase I (TOP1) inhibitor-based antibody drug conjugates...
Themefolio
Profiler
Peergroup
© BusinessWire
19.08.2024
ZNTL
LISTED
NASDAQ
Newman Ferrara LLP Announces Corporate Governance Investigation of Zentalis Pharmaceuticals, Inc. – ZNTL
News Preview
Newman Ferrara LLP announced today that the firm is conducting an investigation on behalf of shareholders of Zentalis Pharmaceuticals, Inc. (“Zentalis” or the “Company”) (NASDAQ:ZNTL) into potential breaches of fiduciary duty by the Company’s Board of Directors (the “Board”).
Zentalis, headquartered in San Diego, CA, is a clinical-stage biopharm...
Themefolio
Profiler
Peergroup
© BusinessWire
13.08.2024
ZNTL
LISTED
NASDAQ
Zentalis Pharmaceuticals, Inc. (ZNTL) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
News Preview
Attorney Advertising-- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Zentalis Pharmaceuticals, Inc. (“Zentalis” or “the Company”) (NASDAQ: ZNTL). Investors who purchased Zentalis securities are encouraged to obtain additional information and assist the investigation by visiting the firm’s site:...
Themefolio
Profiler
Peergroup
© Globe Newswire
09.08.2024
ZNTL
LISTED
NASDAQ
Zentalis Pharmaceuticals Reports Second Quarter 2024 Financial Results and Operational Progress
News Preview
$426.4M cash, cash equivalents and marketable securities as of June 30, 2024;Projected cash runway into mid-2026...
Themefolio
Profiler
Peergroup
© Globe Newswire
01.08.2024
ZNTL
LISTED
NASDAQ
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
News Preview
SAN DIEGO, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company discovering and developing clinically differentiated small molecule therapeutics targeting fundamental biological pathways of cancers, today announced that on August 1, 2024, the Compensation Committee of Zentali...
Themefolio
Profiler
Peergroup
© Globe Newswire
01.07.2024
ZNTL
LISTED
NASDAQ
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
News Preview
SAN DIEGO, July 01, 2024 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company discovering and developing clinically differentiated small molecule therapeutics targeting fundamental biological pathways of cancers, today announced that on July 1, 2024, the Compensation Committee of Zentalis’...
Themefolio
Profiler
Peergroup
© Globe Newswire
18.06.2024
ZNTL
LISTED
NASDAQ
Zentalis Pharmaceuticals Provides Update on Azenosertib Clinical Development Program
News Preview
FDA has placed a partial clinical hold on ZN-c3-001, DENALI and TETON monotherapy studies of azenosertib...
Themefolio
Profiler
Peergroup
© Globe Newswire
03.06.2024
ZNTL
LISTED
NASDAQ
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
News Preview
NEW YORK & SAN DIEGO, June 03, 2024 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company discovering and developing clinically differentiated small molecule therapeutics targeting fundamental biological pathways of cancers, today announced that on June 3, 2024, the Compensation Committ...
Themefolio
Profiler
Peergroup
© Globe Newswire
23.05.2024
ZNTL
LISTED
NASDAQ
Zentalis Pharmaceuticals to Present Promising Results from Phase 1 Trial of Azenosertib and Gemcitabine in Relapsed or Refractory Osteosarcoma at 2024 American Society of Clinical Oncology Annual Meeting
News Preview
Administration of azenosertib combined with gemcitabine was well tolerated and resulted in clinically meaningful increase in event-free survival compared to historical comparators...
Themefolio
Profiler
Peergroup
© Globe Newswire
07.05.2024
ZNTL
LISTED
NASDAQ
Zentalis Pharmaceuticals Reports First Quarter 2024 Financial Results and Operational Progress
News Preview
Azenosertib clinical development plan on track with multiple data readouts in gynecological and other cancer types anticipated in the second half of 2024 and into 2025...
Themefolio
Profiler
Peergroup
© Globe Newswire
01.05.2024
ZNTL
LISTED
NASDAQ
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
News Preview
NEW YORK and SAN DIEGO, May 01, 2024 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company discovering and developing clinically differentiated small molecule therapeutics targeting fundamental biological pathways of cancer, today announced that on May 1, 2024, the Compensation Committee of...
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
More information, click here
More sector specific news
Your Press Release is missing or you want share news over GICS11? Drop us a line.
